INVESTORS

Press Releases

Year

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

August 24, 2026

-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD – -First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center– DURHAM, N.C. --(BUSINESS WIRE)--Aug. 24, 2026-- Precision BioSciences, Inc....

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining - - In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA...

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

July 31, 2026

DURHAM, N.C. --(BUSINESS WIRE)--Jul. 31, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial...

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

July 27, 2026

– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy – DURHAM, N.C. --(BUSINESS WIRE)--Jul. 27, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its...

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2026

DURHAM, N.C. --(BUSINESS WIRE)--Jul. 10, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the...

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

June 29, 2026

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 29, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000...

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

May 27, 2026

- New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts - - In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase...

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

May 21, 2026

- Webcast with Hepatitis B experts to discuss new biopsy and clinical data from the ongoing ELIMINATE-B trial in chronic hepatitis B - - Webcast will be held May 27 th, 2026, at 8:00 AM EDT - DURHAM, N.C. --(BUSINESS WIRE)--May 21, 2026-- Precision BioSciences, Inc....

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 14, 2026

– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice – – Findings further support evaluation of PBGENE-DMD in DMD patient populations as young...

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026

- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 - - Advanced PBGENE-DMD toward clinical evaluation in the Phase 1/2...

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 26

Investors

Events & Presentations
Press Releases
Corporate Deck
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Sustainability
Investor FAQs

Investor Tools

Print Page
Email Alerts
Contact IR
RSS Feeds

INVESTORS

Press Releases

Investors

Investor Tools

Contact Info

Learn More

Policies